MedTrace Logo

Amyloid Imaging With 11C-PiB in Healthy Aging and Mild Cognitive Impairment

NCT04505735 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 25

Last updated 2023-04-07

No results posted yet for this study

Summary

The purpose of this study is to measure the amount of amyloid in the brain. Amyloid is a protein found in the brain of patients with Alzheimer's disease and can be detected using a Positron Emission Tomography (PET) scan. This study is interested in how amyloid levels in the brain relate to memory and thinking abilities.

Conditions

  • Alzheimer Disease
  • Healthy Aging

Interventions

DRUG

11C-PiB

Pittsburgh Compound-B (11C-PiB) is a diagnostic imaging agent that binds to beta-amyloid plaques and allows them to be viewed using positron emission tomography (PET) imaging.

Sponsors & Collaborators

  • University of Colorado, Denver

    lead OTHER

Principal Investigators

  • Brianne M Bettcher, Ph.D. · University of Colorado, Denver

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-11-22
Primary Completion
2022-09-23
Completion
2022-09-23
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04505735 on ClinicalTrials.gov